奥扎格雷联合丹红注射液治疗急性冠脉综合征临床研究

The clinical technical study reports on treating the acute Coronary syndrome（ACS） with and ozagrel danhong Zhusheye

目的：探讨奥扎格雷联合丹红注射液替代口服阿司匹林治疗急性冠脉综合征（ACS）的临床疗效。方法：100例急性冠脉综合征患者随机分成奥扎格雷联合丹红注射液50例为治疗组，常规治疗50例为对照组，治疗组在常规治疗基础上用奥扎格雷加丹红注射液替代口服阿司匹林，奥扎格雷80mgQd，丹红注射液20mlQd，两药均用2周，对照组常规治疗（阿司匹林、硝酸酯类、钙离子拮抗剂、β受体阻滞剂、溶栓等）。两组分别于入院后即刻和治疗后2周抽静脉血，检测血小板聚集率，血浆纤维蛋白原水平和全血粘度，观察临床疗效及安全性。结果：两组患者治疗前血小板聚集率、血浆纤维蛋白原水平及全血粘度均升高，两组间无差异，治疗2周后两组均有所下降，治疗组下降与对照纽比较有显著性差异（P〈0．05），临床疗效也较对照组明显改善（P〈0．05）。结论：奥扎格雷联合丹红注射液可完全替代阿司匹林治疗急性冠脉综合征，临床疗效显著。

Objective： To observe the clinical effect on treating the Acute coronary syndrome（ACS） with Danhong Zhusheye and Ozagrel instead of aspirin. Methods 100 ACS patients were devided into two groups randomly.Each group contain 50 patients.The control group were treated with conventional therapy（Aspirin, nitrate esters, calcium ions antagonist, beta blocker, thrombolysis etc）;The treatment group were treated with Danhong Zhusheye and Ozagrel instead of Aspirin for 2 weeks,other treatment measure were the same as control group. The changing of platelet aggregation ratio, plasma fibrinogen, blood viscosity were observed.The clinical effects and security were also observed. Results There were no difference of platelet aggregation ratio, plasma fibrinogen, blood viscosity between two groups before treatment.After 2 weeks,the two groups＇ platelet aggregation ratio, plasma fibrinogen, blood viscosity were descend. The changing of platelet aggregation ratio, plasma fibrinogen, blood viscosity were difference significantly between two groups （P〈0.05）;The clinical effects were improved ,the difference were significant between two groups （P〈0.05）. Conclusion The Danhong Zhusheye and Ozagrel instead of Aspirin can be used for the treatment of ACS absolutely, their clinical effect is remarkble.